

**UPNEEQ**  
(oxymetazoline hydrochloride  
ophthalmic solution), 0.1%

## Imagine an EYE-OPENING Lift with a Daily Drop of Upneeq®<sup>1</sup>

The only FDA-approved prescription eyedrop proven to raise upper eyelids  
in adults with acquired blepharoptosis (low-lying lids)<sup>1</sup>

### Examples of positive results after the first dose of Upneeq



**Before Upneeq**



**Hour 2**



**Before Upneeq**



**Minute 30**



**Before Upneeq**



**Hour 2**

Actual patient images courtesy of Dr. Raymond Douglas. Individual results may vary.

Average upper eyelid lift with Upneeq in clinical trials was 1 mm.\*<sup>2</sup>

\*Two randomized, multicenter, double-masked, vehicle-controlled, Phase 3 studies compared once-daily Upneeq in 304 subjects with acquired blepharoptosis. Efficacy was assessed by points seen in the superior visual field using Leicester Peripheral Field Test (LPFT) and photographic measurement of Marginal Reflex Distance-1 (MRD-1). There was a statistically significant difference in mean change in the number of points seen in the superior visual field from baseline after instillation of Upneeq and vehicle, with significantly greater increases in the study eye of the Upneeq group evident at the 2-hour point and maintained at the 6-hour time point. Greater eyelid lift (increased MRD-1) was observed for the Upneeq group than the vehicle group on Day 1 at 6 hours post-dose and on Day 14 at 2 hours post-dose.<sup>1</sup>

#### **IMPORTANT SAFETY INFORMATION INDICATION**

Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.

#### **WARNINGS AND PRECAUTIONS**

- Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses. Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.

**Please see Important Safety Information continued on next page.**

**Please see accompanying full Prescribing Information and Patient Information.**

**UPNEEQ**<sup>®</sup>  
(oxymetazoline hydrochloride  
ophthalmic solution), 0.1%

# Imagine an EYE-OPENING Lift with a Daily Drop of Upneeq<sup>®</sup>1

The only FDA-approved prescription eyedrop proven to raise upper eyelids  
in adults with acquired blepharoptosis (low-lying lids)<sup>1</sup>

## Examples of positive results after the first dose of Upneeq



**Before Upneeq**



**Minute 15**



**Before Upneeq**



**Hour 1**

### WARNINGS AND PRECAUTIONS

- Alpha-adrenergic agonists as a class may impact blood pressure. Advise Upneeq patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
- Use Upneeq with caution in patients with cerebral or coronary insufficiency or Sjögren's syndrome. Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
- Upneeq may increase the risk of angle closure glaucoma in patients with untreated narrow-angle glaucoma. Advise patients to seek immediate medical care if signs and symptoms of acute narrow-angle glaucoma develop.
- Patients should not touch the tip of the single patient-use container to their eye or to any surface, in order to avoid eye injury or contamination of the solution.

### ADVERSE REACTIONS

Adverse reactions that occurred in 1-5% of subjects treated with Upneeq were punctate keratitis, conjunctival hyperemia, dry eye, blurred vision, instillation site pain, eye irritation, and headache.

### DRUG INTERACTIONS

- Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy.
- Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

**To report SUSPECTED ADVERSE REACTIONS or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report SUSPECTED ADVERSE REACTIONS to the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). Please see accompanying full Prescribing Information and Patient Information.**

**References:** 1. Upneeq<sup>®</sup> (oxymetazoline hydrochloride ophthalmic solution), 0.1%. [Prescribing Information]. RVL Pharmaceuticals, Inc; 2021.  
2. Data on file. RVL Pharmaceuticals, Inc.

Distributed by: RVL Pharmaceuticals, Inc.  
Bridgewater, NJ 08807  
Customer Service 1-866-600-4799

**RVL**  
PHARMACEUTICALS, INC.

Upneeq is a registered trademark  
of RVL Pharmaceuticals, Inc.  
©2021 RVL Pharmaceuticals, Inc.  
PM-US-UPN-0763 12/21

Download this  
flashcard at  
[Upneeq.com](http://Upneeq.com)

